Oncoquest™, manufactured using AGGREGON™ technology, is a personalized (autologous) therapeutic cancer vaccine that is prepared from the patient’s own tumor cells in combination with a focused delivery to the immune system of high dose powerful immune stimulators. Scientists from XEME developed this vaccine by taking advantage of the natural ability of the immune system to fight infections and malignant cells. AGGREGON™ vaccines are designed to stimulate the immune system to fight effectively against cancer progression and provide continuous protection against tumor relapse and spread (metastases).
The technology was developed and patented by XEME scientists while working at Biomira Inc. and is protected by 2 patents (Patents: US 6,544,549 B1, US 6,312,718 B1). XEME has exclusively licensed rights to use of this technology from Oncothyreon, Inc., a publicly traded Delaware corporation (successor to Biomira Inc.). The licenses are exclusive for various categories of vaccines including therapeutic cancer vaccines for both human and veterinary uses. XEME has also registered with the United States Patent and Trademark Office (“USPTO”) the trademark Aggregon™ and Oncoquest™ for use in its initial family of vaccine products. Additionally, XEME has three patent-pending applications with the USPTO for extension to the Aggregon family (Application #s 62292029, 62292269 and 62293506) that should afford significant long term patent protection. XEME is in the process of drafting additional applications that relate to technology different from those in the licensed patents.
For more information on the science behind the AGGREGON™ technology see: Immunology Background
For more information on the manufacture of XEME’s products see: Preparation of AGGREGON™ Vaccine
For more information on pre-clinical and clinical studies supporting the use of XEME’s AGGREGON™ vaccine see: Experimental & Clinical Evidence
For more information on the unique advantages of XEME’s technology see: Why XEME’s Vaccine?